HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Revlon credit

This article was originally published in The Rose Sheet

Executive Summary

Amendment to firm's credit facility, approved unanimously by bank group, includes one-year extension of the waiver to EBITDA and other financial covenants received by Revlon last year under the credit agreement, company announces Jan. 29. Amendment reflects "continued support of the company's progress against its growth plan," Revlon states. Under the amendment, company's financial covenants have been waived for the four fiscal quarters ending Dec. 31, 2003, eliminated for the first three quarters of 2004 and waived through Jan. 31, 2005 for the four fiscal quarters ending Dec. 31, 2004. It also continues the $20 mil. minimum liquidity covenant established with the 2003 credit agreement and extends the $65 mil. line of credit provided by MacAndrews & Forbes from Dec. 1, 2005 to June 30, 2005. Interest rate for loans under the agreement will increase by .25%...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS011870

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel